soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 was associated with lower risk of composite heart failure in people with type 2 diabetes and baseline heart failure in the randomized clinical SOUL trial shows oral semaglutide

The steadier blood concentration can also simplify meal timing and activity planning because you're less likely to experience the appetite-suppression swings that some people notice before their next once-weekly injection is due

But they are not interchangeable, and the right choice depends on how each medication works, your medical history, and how your body responds during treatment

The estimated half-life of CJC-1295 (with DAC) was 5.8 to 8.1 days, confirming its extended duration of action

Blood Sugar Concern Glucagon's primary job is raising blood sugar, so you might expect problems with retatrutide

What does all of this mean for you